Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2016

01-11-2016 | Original Article

Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease

Authors: Preeti Sharma, Shushruta Bhunia, Satish S. Poojary, Dinesh S. Tekcham, Mustafa Ahmed Barbhuiya, Sanjiv Gupta, Braj Raj Shrivastav, Pramod Kumar Tiwari

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

Promoter methylation in various tumor suppressor genes is reported to influence gallbladder carcinogenesis. Here, we aimed to identify methylation status in gallbladder cancer (GBC) by performing a comprehensive genome-wide DNA methylation profiling. The methylation status of 485,577 CpG sites were investigated using Illumina’s Infinium Human Methylation 450 BeadChip array in 24 tissues (eight each of tumor, adjacent non-tumor, and gallstone). About 33,443 differentially methylated sites (DMRs) were obtained in the whole human genome, of which 24,188 (72 %) were hypermethylated and 9255 (28 %) were hypomethylated. The data also revealed that majority of the DMRs are localized on the proximal promoter region [Transcription start sites (TSS200, TSS1500) and 5′ untranslated region (5′UTR)] and first exon. Exclusion of first exon detected a total of 10,123 (79 %) hypermethylated and 2703 (21 %) hypomethylated sites. Comparative analysis of the later with our differential proteomics data resulted in identification of 7 hypermethylated or down-regulated (e.g., FBN1, LPP, and SOD3) and 61 hypomethylated or up-regulated markers (e.g., HBE1, SNRPF, TPD52) for GBC. These genes could be further validated on the basis of their methylation/expression status in order to identify their utility to be used as biomarker/s for early diagnosis and management of GBC.
Appendix
Available only for authorised users
Literature
1.
Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118:1591–602.CrossRefPubMed
2.
Medina E, Kaempffer AM. Cancer mortality in Chile: epidemiological considerations. Rev Med Chil. 2001;129:1195–202.CrossRefPubMed
3.
Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.CrossRefPubMed
4.
Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Burgos L. Gallbladder cancer in the IX Region of Chile. Impact of the anatomopathological study of 474 cases. Rev Med Chil. 1994;122:1248–56.PubMed
5.
Barbhuiya MA, Singh TD, Poojary SS, Gupta S, Kakkar M, Shrivastav BR, et al. Gallbladder cancer incidence in Gwalior district of India: five-year trend based on the registry of a regional cancer center. Indian J Cancer. 2015;52:430–7.CrossRefPubMed
6.
Dutta U, Nagi B, Garg PK, Sinha SK, Singh K, Tandon RK. Patients with gallstones develop gallbladder cancer at an earlier age. Eur J Cancer Prev. 2005;14:381–5.CrossRefPubMed
7.
8.
Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin N Am. 2010;39:157–69.CrossRef
9.
Csendes A, Becerra M, Rojas J, Medina E. Number and size of stones in patients with asymptomatic and symptomatic gallstones and gallbladder carcinoma: a prospective study of 592 cases. J Gastrointest Surg. 2000;4:481–5.CrossRefPubMed
10.
Mlinarić-Vrbica S, Vrbica Z. Correlation between cholelithiasis and gallbladder carcinoma in surgical and autopsy specimens. Coll Antropol. 2009;33:533–7.PubMed
11.
Le MD, Henson D, Young H, Albores-Saavedra J. Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy? Ann Hepatol. 2011;10:306–14.PubMed
12.
Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treatment. 2012;44:11–24.CrossRef
13.
Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009;20:146–59.CrossRefPubMed
14.
15.
16.
Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19:698–711.CrossRefPubMed
17.
Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98:288–95.CrossRefPubMed
18.
Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium Methylation 450K technology. Epigenomics. 2011;3:771–84.CrossRefPubMed
19.
Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, et al. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics. 2009;1:177–200.CrossRefPubMed
20.
Marabita F, Almgren M, Lindholm ME, Ruhrmann S, Fagerström-Billai F, Jagodic M, et al. An evaluation of analysis pipelines for DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Epigenetics. 2013;8:333–46.CrossRefPubMedPubMedCentral
21.
Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advani J, et al. Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics. BBRC. 2014;446:863–9.PubMedPubMedCentral
22.
Wilhelm-Benartzi CS, Koestler DC, Karagas MR, Flanagan JM, Christensen BC, Kelsey KT, et al. Review of processing and analysis methods for DNA methylation array data. Br J Cancer. 2013;109:1394–402.CrossRefPubMedPubMedCentral
23.
Laurent L, Wong E, Li G, Huynh T, Tsirigos A, Ong CT, et al. Dynamic changes in the human methylome during differentiation. Genome Res. 2010;20:320–31.CrossRefPubMedPubMedCentral
24.
Li Y, Zhu J, Tian G, Li N, Li Q, Ye M, et al. The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol. 2010;8:1–9.CrossRef
25.
26.
Milutin Gašperov N, Farkas SA, Nilsson TK, Grce M. Epigenetic activation of immune genes in cervical cancer. Immunol Letters. 2014;162:256–7.CrossRef
27.
Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Can Res. 2011;17:5582–92.CrossRef
28.
Cheng YI, Yan Z, Liu Y, Liang C, Xia H, Feng J, et al. Analysis of DNA methylation patterns associated with the gastric cancer genome. Oncol Lett. 2014;7:1021–6.PubMedPubMedCentral
29.
Naumov VA, Generozov EV, Zaharjevskaya NB, Matushkina DS, Larin AK, Chernyshov SV, et al. Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics. 2013;8:921–34.CrossRefPubMedPubMedCentral
30.
Li X, Zhou F, Jiang C, Wang Y, Lu Y, Yang F, et al. Identification of a DNA methylome profile of esophageal squamous cell carcinoma and potential plasma epigenetic biomarkers for early diagnosis. PLoS One. 2014;9:1–12.
31.
Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A comprehensive overview of Infinium HumanMethylation450 data processing. Brief Bioinform. 2014;15:929–41.CrossRefPubMed
32.
Price ME, Cotton AM, Lam LL, Farré P, Emberly E, Brown CJ, et al. Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenet Chromatin. 2013;6:1–2.CrossRef
33.
34.
Simmer F, Brinkman AB, Assenov Y, Matarese F, Kaan A, Sabatino L, et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics. 2012;7:1355–67.CrossRefPubMedPubMedCentral
35.
Hinoue T, Weisenberger DJ, Lange C, Shen H, Byun HM, Van Den Berg, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22:271–82.CrossRefPubMedPubMedCentral
36.
Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND, et al. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One. 2016;6:1–12.
37.
Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6:692–702.CrossRefPubMed
38.
Guo Q, Song Y, Zhang H, Wu X, Xia P, Dang C. Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients. Med Oncol. 2013;30:695.CrossRefPubMed
39.
Kuriyama S, Yoshida M, Yano S, Aiba N, Kohno T, Minamiya Y, et al. LPP inhibits collective cell migration during lung cancer dissemination. Oncogene. 2016;35:952–64.CrossRefPubMed
40.
Kim J, Mizokami A, Shin M, Izumi K, Konaka H, Kadono Y, et al. SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation. Anticancer Res. 2014;34:2821–31.PubMed
41.
42.
Lee SH, Appleby V, Jeyapalan JN, Palmer RD, Nicholson JC, Sottile V, et al. Variable methylation of the imprinted gene, SNRPN, supports a relationship between intracranial germ cell tumours and neural stem cells. J Neuro oncol. 2011;101:419–28.CrossRef
43.
Byrne JA, Frost S, Chen Y, Bright RK. Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumor Biol. 2014;35:7369–82.CrossRef
44.
Singh TD, Poojary S, Bhunia S, Barbhuiya MA, Gupta S, Shrivastav BR, et al. Epigenetic regulation of APC in the molecular pathogenesis of gallbladder cancer. Indian J Med Res. 2016 (in press).
45.
46.
47.
Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci. 2003;100:15853–8.CrossRefPubMedPubMedCentral
48.
Barbhuiya MA, Sahasrabuddhe NA, Pinto SM, Muthusamy B, Singh TD, Nanjappa V, et al. Comprehensive proteomic analysis of human bile. Proteomics. 2011;11:4443–53.CrossRefPubMed
49.
Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327:1650–3.CrossRefPubMedPubMedCentral
50.
He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44:2850–9.CrossRefPubMed
51.
Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859–68.CrossRefPubMed
52.
Möller C, Strömberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia. 2003;17:203–10.CrossRefPubMed
53.
Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000;6:3530–5.PubMed
54.
Hwang JH, Hwang JH, Chung HK, Kim DW, Hwang ES, Suh JM, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocr Metab. 2003;88:408–16.CrossRefPubMed
55.
56.
Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I. Angiopoietin-2 stimulates breast cancer metastasis through the α5β1 integrin-mediated pathway. Cancer Res. 2007;67:4254–63.CrossRefPubMedPubMedCentral
57.
Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001;20:4995–5004.CrossRefPubMed
58.
Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the β4 integrin and the PI3k pathway. Oncogene. 2007;26:2082–94.CrossRefPubMed
59.
Agrez MV, Bates RC. Colorectal cancer and the integrin family of cell adhesion receptors: current status and future directions. Eur J Cancer. 1994;30:2166–70.CrossRef
60.
Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci. 2003;74:675–96.CrossRefPubMed
61.
Liebert M, Washington R, Stein J, Wedemeyer G, Grossman HB. Expression of the VLA beta 1 integrin family in bladder cancer. Am J Pathol. 1994;144:1016–22.PubMedPubMedCentral
62.
Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840–55.CrossRefPubMed
63.
Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4:909–14.CrossRefPubMed
64.
Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV. Constitutive activation of transcription factors NF-κB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinogen. 1999;26:119–29.CrossRef
65.
Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3:582–91.CrossRefPubMed
66.
Szepeshazi K, Schally AV, Nagy A, Halmos G. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas. 2005;31:275–82.CrossRefPubMed
67.
Palmer JS, Duffy DL, Box NF, Aitken JF, O’Gorman LE, Green AC, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet. 2000;66:176–86.CrossRefPubMed
Metadata
Title
Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease
Authors
Preeti Sharma
Shushruta Bhunia
Satish S. Poojary
Dinesh S. Tekcham
Mustafa Ahmed Barbhuiya
Sanjiv Gupta
Braj Raj Shrivastav
Pramod Kumar Tiwari
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5355-9

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue

Original Article

RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC

Original Article

Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis

Review

Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis

Original Article

Upregulation of miR-192 inhibits cell growth and invasion and induces cell apoptosis by targeting TCF7 in human osteosarcoma

Original Article

Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma

Original Article

The anticancer effects of Resina Draconis extract on cholangiocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits